| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42d3020ad67c717f34d32e1448c74281 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2018-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81361b76d928eaba549e0999cf5a1632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec7657bd8b240976fff60727b0369793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b53dd071bb2a9ebf64a59ff96472b4f2 |
| publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019345496-A1 |
| titleOfInvention |
Antisense oligonucleotides for modulating relb expression |
| abstract |
The present invention relates to antisense oligonucleotides that are capable of modulating expression of RelB in a target cell. The oligonucleotides are complementary to mammalian RELB pre-mRNA sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023144357-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4219764-A1 |
| priorityDate |
2017-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |